EUVIMEDEUVIMED entdecken
Crossref

Iatrogenic endocrine complications of lithium therapy

Marie-Christine Vantyghem

Annales d'Endocrinologie · 2023

DOI: 10.1016/j.ando.2023.03.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annales d'Endocrinologie, 2023. Verfasst von Marie-Christine Vantyghem. Beteiligte Einrichtung: CHU de Lille, Endocrinology, Diabetology, Metabolism and Nutrition, 59000 Lille, France; Inserm U1190, 59000 Lille, France; Université de Lille, 5900…. Hauptthemen laut MEDLINE: Diabetes Insipidus, Nephrogenic, Hyperthyroidism, Hypothyroidism, Goiter. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lithium is a cation, similar to sodium and potassium, affecting ion transport. It is used in the medical field as a treatment of bipolar disorders. The main endocrine complications of lithium treatment affect thyroid and parathyroid glands, in association with renal complications. Thyroid adverse effects, which are more frequent in women, comprise hypothyroidism, goiter, or sometimes hyperthyroidism, through interference with the iodine symporter. The increase in thyroid volume is early. Prevalence of goiter is 4 times higher than in the general population and hypothyroidism (8-20%) more frequent in case of pre-existing thyroid autoimmunity. Hyperthyroidism likely to worsen mood is reported in 5% of cases but the causal link to lithium is unproven. An increase in serum calcium and PTH occurs in 30% of cases, as lithium stimulates parathyroid cell proliferation by activating the Wnt pathway. The risk of hyperparathyroidism, by adenoma and especially by hyperplasia, is 5 times higher than in the general population, with the particularity of frequent low urine calcium by action on the calcium-sensing receptor (CaSR). Renal complications include risk of acute or chronic renal failure and nephrogenic diabetes insipidus, which is a factor for hypernatremia and hypercalcemia through dehydration. Nephrogenic diabetes insipidus is not always reversible after lithium therapy discontinuation. Metabolically, weight gain can be observed, but rather less than with other psychotropic drugs, and lithium does not in itself induce diabetes. At pituitary level, corticotropic activation is frequent, but implicating the disease rather than lithium. Lithium treatment induces little or no hyperprolactinemia. Regular monitoring of serum calcium, the ionogram, creatinine and TSH is recommended in lithium treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Insipidus, NephrogenicHyperthyroidismHypothyroidismGoiterHumansFemaleLithiumCalciumLithium CompoundsIatrogenic Disease

Stichwörter der Autor:innen

DiabetesDiabetes insipidusDiabèteDiabète insipideGonadGonadesHypercalcemiaHypercalcémieLithiumPoidsProlactinProlactineThyroidThyroïdeWeight

Substanzen

LithiumCalciumLithium Compounds

Autor:innen und Institutionen

  • CHU de Lille, Endocrinology, Diabetology, Metabolism and Nutrition, 59000 Lille, France; Inserm U1190, 59000 Lille, France; Université de Lille, 59000 Lille, France. Electronic address: mc-vantyghem@chru-lille.fr.

Zitieren

APA

Vantyghem, M. C. (2023). Iatrogenic endocrine complications of lithium therapy. Annales d'Endocrinologie. https://doi.org/10.1016/j.ando.2023.03.004

Vancouver

Vantyghem MC. Iatrogenic endocrine complications of lithium therapy. Annales d'Endocrinologie. 2023. doi:10.1016/j.ando.2023.03.004

BibTeX
@article{Vantyghem2023,
  author = {Vantyghem, Marie-Christine},
  title = {Iatrogenic endocrine complications of lithium therapy},
  journal = {Annales d'Endocrinologie},
  year = {2023},
  doi = {10.1016/j.ando.2023.03.004}
}
Kostenlos starten →